Bavaria Elevates Pharmaceutical Supply to Top Priority

Bavaria's Health Minister has declared the assurance of pharmaceutical supply as a top priority. During the 10th Bavarian Pharmaceutical Summit, Health Minister Judith Gerlach and Economic Minister Hubert Aiwanger engaged with key stakeholders from politics, the pharmaceutical sector, and healthcare to address current challenges in drug supply and discuss the future of research and development in Germany and the European Union.

Gerlach emphasized the critical need for reliable frameworks and incentives to retain and expand the pharmaceutical industry within Bavaria. She highlighted the increasing dependency of Europe on countries like China and India for drug supplies, underscoring the necessity for Europe to enhance its attractiveness for pharmaceutical investments.

Over the past decade, collaborative efforts at the Bavarian Pharmaceutical Summit have initiated significant developments, positioning Bavaria as a leader in the nation. Successful outcomes from previous summits include the substantial influence on the Medical Research Act and legislation aimed at combating supply shortages of off-patent medications while improving access to pediatric drugs. Additionally, Bavaria is actively participating in steering research funding and integrating cancer registry data.

To bolster the innovative capabilities and competitiveness of the pharmaceutical industry, continued dialogue remains essential. Gerlach noted that early identification of problems and challenges, coupled with collaborative efforts, can lead to mutual benefits. A central aspect of this approach is the creation of an environment that minimizes unnecessary bureaucracy.